Ultragenyx (RARE) provided a corporate update. 2026 Clinical and Regulatory Catalysts: DTX401 – Biologics License Application rolling submission completed in December 2025; UX111 – Resubmission of the BLA is on track for early in 2026; GTX-102 – ata from the fully enrolled, pivotal, Phase 3 Aspire study in patients with a genetically confirmed diagnosis of UBE3A deletion is expected in the second half of 2026; UX701 – Enrollment is complete for the fourth cohort in the ongoing, dose-finding stage of the pivotal Cyprus2+ study. Data are expected in the first half of 2026
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RARE:
- Ultragenyx reports preliminary FY25 revenue $672M-$674M, consensus $655.9M
- Ultragenyx price target lowered to $50 from $55 at Morgan Stanley
- Ultragenyx: Trial Setback Creates Buying Opportunity as Diversified Pipeline and Commercial Base Support $60 Target
- Ultragenyx price target lowered to $60 from $80 at H.C. Wainwright
- Ultragenyx price target lowered to $52 from $64 at Guggenheim